For research use only. Not for use in humans.

Necitumumab (anti-EGFR)

Synonyms: ERBB1， HER1 Cat.No.A2048 Purity:98%

Necitumumab (anti-EGFR) is an epidermal growth factor receptor (EGFR) antagonist that can be used in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous non-small cell lung cancer.

Click to purchase the isotype control of Necitumumab (anti-EGFR)

1 Citation

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A204801 Purity: 98% Protein concentration: 4.6mg/ml Endotoxin Level: <1 EU/mg

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

Featured Inhibitors	Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933

Specificity

Name	Citation	EGFR/ErbB1	HER2/ErbB2	ErbB3	ErbB4	mutant EGFR	Others
Saracatinib (AZD0530)	312	+++					c-Src,c-YES,LCK
Canertinib (CI-1033)	51	++++	+++
AG-490	132	+					JAK2 (V617F)
CP-724714	109		++
WZ4002	34	++++
Sapitinib (AZD8931)	50	+++	+++	+++
CUDC-101	23	+++	++				HDAC,HDAC1,HDAC6
AG-1478	100	+++
PD153035 HCl	20	++++
Pelitinib (EKB-569)	11	+	+				Src,MEK/ERK,Raf
AEE788 (NVP-AEE788)	16	++++	+++		+		c-Abl,FLT1,c-Fms
AC480 (BMS-599626)	12	++	++		+
AP26113-analog (ALK-IN-1)	5					++	ALK,IGF1R,INSR
WZ3146	2	++++
Allitinib tosylate	19	++++	+++		++++
Rociletinib (CO-1686)	37	++
Varlitinib	8	+++	++++
Icotinib (BPI-2009H)	11	+++
TAK-285	5	++	++		+		MEK1,Aurora B,LCK
WHI-P154	11	+++					Src,VEGFR,JAK3
Daphnetin	4	+					PKA,PKC
PD168393	6	++++
CNX-2006	2	++				++
Tyrphostin 9	2	+					PDGFR
AG-18	1	+
Icotinib Hydrochloride	0	+++
HS-10296 hydrochloride	3					++++
MTX-531	0	++					PI3Kα
Avitinib maleate	0	+++				++++	BTK
limertinib	0					++++
AG 825	0		+				PDGFR
4-AMino-1-phenylpyrazolo[3,4-d]pyriMidine	1	+
AST-1306	10	++++	+++		++++
ErbB2 inhibitor	0		+		+
Tuxobertinib (BDTX-189)	3	++++	++++				RIPK2,BLK
Epertinib hydrochloride	1	++++	+++		+++
JND3229	0	+++				++	EGFR C797S
BI-4020	1					++++
Tyrphostin AG-528	0	+	+
AG 556	0	+
Canertinib dihydrochloride	8	+++	+++
EGFR Inhibitor	4	++					Microtubules
SU5214	0	+					VEGFR2
RG 13022	0	+
TQB3804	1					++++
zipalertinib (TAS6417)	5	+++			+++	++++	TXK,BMX
Pyrotinib dimaleate	6	++	++
PD153035	14	++++
AG 494	0	+
AG 555	1	+
Theliatinib (HMPL-309)	0	+++				++
Avitinib (Abivertinib)	3					++++	JAK3,BTK
Lazertinib (YH25448)	9	++++				++++	Del19,L85R
Lifirafenib (BGB-283)	8	++				+	WT A-RAF,C-RAF (Y340/341D),BRAF(V600E)
Nazartinib (EGF816)	6	++				++
Zorifertinib (AZD3759)	7	++++
CL-387785 (EKI-785)	5	++++
Poziotinib (NOV120101, HM781-36B)	37	+++	+++		++
AZ5104	6	++++			+++		ACK1,BLK,BRK
AV-412 free base	0	++++	++			++++
HER2-Inhibitor-1	1		✔
WZ8040	3	✔
Genistein	38	✔					topo II
Rezivertinib	1	✔
BDTX-1535	0	✔
Falnidamol	1	✔
BLU-945	1	✔
(S)-Sunvozertinib ((S)-DZD9008)	1	✔
CH7233163	1	✔
Licochalcone D	1	✔					NF-κB,PARP,Caspase
Furmonertinib Mesylate (AST2818, Alflutinib)	3	✔					CYP3A4
(Rac)-JBJ-04-125-02	0	✔
Tyrphostin AG30 (AG30)	0	✔
AG-1557	0	✔
AG99	0	✔
MTX-211	2	✔					PI3K
RG14620	0	✔					ABCG2
Almonertinib (HS-10296)	4					✔
Cyasterone	1	✔
Norcantharidin	5	✔					c-Met
Naquotinib(ASP8273)	2	✔
EAI045	3					✔
Olmutinib (BI 1482694)	6	✔					BTK
Butein	3	✔
Chrysophanic Acid	3	✔					mTOR
EGCG ((-)-Epigallocatechin Gallate)	42	✔					DNMT,telomerase,FASN

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Necitumumab (anti-EGFR) is an epidermal growth factor receptor (EGFR) antagonist that can be used in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous non-small cell lung cancer.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	906805-06-9
Molecular Weight	150 kDa
Isotype	human IGg1, κ
Application	Necitumumab (anti-EGFR)
Source	CHO
Purification	Protein G
Sterility	0.2 μM filtered
Formulation	PBS Buffer, PH 7.4
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07544992	RECRUITING		Recurrent Astrocytoma, IDH-Mutant, Grade 4; Recurrent Glioblastoma, IDH-Wildtype	City of Hope Medical Center	2026-05-26	PHASE1
NCT07318883	NOT_YET_RECRUITING	Drug: HLX07\|Drug: HLX07 placebo\|Drug: Serplulimab\|Drug: Pemb	Squamous NSCLC	Shanghai Henlius Biotech	2026-03	PHASE2; PHASE3
NCT07124884	NOT_YET_RECRUITING	Drug: Administration of experimental treatment association (	Colorectal Carcinoma; KRAS G12C Mutation; Unresectable Colorectal Cancer	Federation Francophone de Cancerologie Digestive	2025-08-31	PHASE2
NCT07459751	RECRUITING	Drug: HLX43\|Drug: HLX43+HLX07\|Drug: Docetaxel	Advanced or Metastatic Squamous Non-Small Cell Lung Cancer	Shanghai Henlius Biotech	2026-05-27	PHASE2; PHASE3
NCT04587128	ACTIVE_NOT_RECRUITING	Drug: Panitumumab\|Drug: Cetuximab\|Drug: Irinotecan\|Drug: FOL	Metastatic Colorectal Cancer	University of Wisconsin, Madison	2020-10-19	PHASE2
NCT07497919	NOT_YET_RECRUITING	Drug: Becotatug Vedotin (recombinant humanized anti-EGFR mAb	Penile Cancer	Fudan University	2026-05-01	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-12)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.